[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT2723869T - Imunocitocinas baseadas em il-15 e domínio sushi de il-15r alfa - Google Patents

Imunocitocinas baseadas em il-15 e domínio sushi de il-15r alfa

Info

Publication number
PT2723869T
PT2723869T PT12731303T PT12731303T PT2723869T PT 2723869 T PT2723869 T PT 2723869T PT 12731303 T PT12731303 T PT 12731303T PT 12731303 T PT12731303 T PT 12731303T PT 2723869 T PT2723869 T PT 2723869T
Authority
PT
Portugal
Prior art keywords
domain based
sushi domain
alpha sushi
based immunocytokines
immunocytokines
Prior art date
Application number
PT12731303T
Other languages
English (en)
Inventor
Daniel Morisseau Sébastien
Teppaz Géraldine
Laurent Joseph Jacques Yannick
Gilbert Marc Robert Bruno
Luc Michel De Martynoff Guy
Bechard David
Original Assignee
Inst Nat Sante Rech Med
Pharma Cytune
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Pharma Cytune filed Critical Inst Nat Sante Rech Med
Publication of PT2723869T publication Critical patent/PT2723869T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT12731303T 2011-06-24 2012-06-22 Imunocitocinas baseadas em il-15 e domínio sushi de il-15r alfa PT2723869T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11358005A EP2537933A1 (en) 2011-06-24 2011-06-24 An IL-15 and IL-15Ralpha sushi domain based immunocytokines

Publications (1)

Publication Number Publication Date
PT2723869T true PT2723869T (pt) 2019-06-04

Family

ID=46456485

Family Applications (1)

Application Number Title Priority Date Filing Date
PT12731303T PT2723869T (pt) 2011-06-24 2012-06-22 Imunocitocinas baseadas em il-15 e domínio sushi de il-15r alfa

Country Status (19)

Country Link
US (5) US20150152188A1 (pt)
EP (3) EP2537933A1 (pt)
JP (4) JP6151687B2 (pt)
KR (4) KR102658284B1 (pt)
CN (3) CN114805606A (pt)
AU (3) AU2012272138B2 (pt)
BR (1) BR112013033350B1 (pt)
CA (1) CA2840113C (pt)
DK (1) DK2723869T3 (pt)
ES (1) ES2727806T3 (pt)
HR (1) HRP20190799T1 (pt)
HU (1) HUE043442T2 (pt)
MX (1) MX354923B (pt)
PL (1) PL2723869T3 (pt)
PT (1) PT2723869T (pt)
RU (2) RU2763298C2 (pt)
SI (1) SI2723869T1 (pt)
TR (1) TR201907397T4 (pt)
WO (1) WO2012175222A1 (pt)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295450B1 (en) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegylated interleukin-10
PT1899364T (pt) 2005-05-17 2020-05-20 Univ Connecticut Composições e métodos para imunomodulação num organismo
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
GB2447187C (en) 2005-12-02 2015-02-04 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
US9303080B2 (en) 2006-01-13 2016-04-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
WO2008054585A2 (en) 2006-09-28 2008-05-08 Schering Corporation Use of pegylated il-10 to treat cancer
ES2642008T3 (es) 2007-05-11 2017-11-14 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
ES2466916T3 (es) 2007-06-27 2014-06-11 Admune Therapeutics Llc Complejos de IL-15 e IL-15R alfa y usos de los mismos
EP2918607B1 (en) 2010-09-21 2017-11-08 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
BR112013018046B1 (pt) 2011-01-18 2023-01-31 Bioniz, Llc Conjugado peptídico, composição farmacêutica, métodos in vitro para bloquear sinalização por um ou mais membros de família citocina-yc e para inibir ligação de citocina-yc a subunidade-yc e uso de conjugado peptídico ou de composição farmacêutica
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP2968525A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai MORBUS NEWCASTLE VIRUSES AND USES THEREOF
US9943568B2 (en) 2013-04-18 2018-04-17 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating cancer
CN109395064A (zh) * 2013-04-19 2019-03-01 赛腾制药 降低的血管渗漏综合征的细胞因子衍生治疗
JP2016528879A (ja) 2013-06-17 2016-09-23 アルモ・バイオサイエンシーズ・インコーポレイテッド タンパク質の同一性および安定性を評価する方法
HUE057598T2 (hu) * 2013-08-08 2022-05-28 Cytune Pharma IL-15 és IL-15R-alfa sushi domén alapú modulokinek
KR102457731B1 (ko) * 2013-08-08 2022-10-21 싸이튠 파마 병용 약학 조성물
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
CN113637692A (zh) * 2014-01-15 2021-11-12 卡德门企业有限公司 免疫调节剂
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
EP2915569A1 (en) * 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016004060A2 (en) * 2014-06-30 2016-01-07 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
JP2017536098A (ja) * 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
PL3235830T3 (pl) * 2014-12-19 2020-12-14 Jiangsu Hengrui Medicine Co., Ltd. Kompleks białkowy interleukiny 15 i jego zastosowanie
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP6730705B2 (ja) * 2015-02-12 2020-07-29 国立大学法人岩手大学 哺乳動物細胞に対する外来遺伝子の導入効率の向上剤
EP3302547A1 (en) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
WO2016200881A1 (en) * 2015-06-10 2016-12-15 Emory University Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
CN112574316A (zh) * 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
WO2017035232A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2017046200A1 (en) * 2015-09-16 2017-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
CN108697736A (zh) 2015-10-06 2018-10-23 明尼苏达大学董事会 治疗性组合物和方法
DK3359556T3 (en) 2015-10-09 2021-08-30 Bioniz Llc Modulering af gamma-c-cytokinaktivitet
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
MA45037A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polythérapie à base d'arnm pour le traitement du cancer
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
AU2017342560B2 (en) 2016-10-14 2022-03-17 Xencor, Inc. IL15/IL15Ralpha heterodimeric Fc-fusion proteins
MX2019004681A (es) 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
JP2019537600A (ja) * 2016-11-02 2019-12-26 ナノプロティアジェン， リミテッド ポリマーナノ粒子
CN108250301A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多靶点嵌合抗原受体
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
TW201904993A (zh) 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
EP3645037A1 (en) 2017-06-27 2020-05-06 Novartis AG Dosage regimens for anti-tim-3 antibodies and uses thereof
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
CA3070095A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
EP3710053A1 (en) 2017-11-16 2020-09-23 Novartis AG Combination therapies
KR20200096253A (ko) 2017-11-30 2020-08-11 노파르티스 아게 Bcma-표적화 키메라 항원 수용체, 및 이의 용도
AU2018381191A1 (en) * 2017-12-08 2020-06-04 Fate Therapeutics, Inc. Immunotherapies using enhanced iPSC derived effector cells
CU24545B1 (es) * 2017-12-29 2021-09-07 Ct Ingenieria Genetica Biotecnologia Péptido antagonista de la actividad de la interleucina-15
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
TWI834636B (zh) 2018-02-26 2024-03-11 美商欣爍克斯公司 Il-15結合物及其用途
JP2021516045A (ja) 2018-02-28 2021-07-01 ファイザー・インク Ｉｌ−１５バリアントおよびその使用
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
EP3561053A1 (en) * 2018-04-26 2019-10-30 Baylor College of Medicine Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
CN110437339B (zh) * 2018-05-04 2021-08-13 免疫靶向有限公司 一种以白介素15为活性成分的融合蛋白型药物前体
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CU20200089A7 (es) 2018-06-01 2021-07-02 Novartis Ag Moléculas de unión contra bcma
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
CN113365663A (zh) 2018-08-30 2021-09-07 Hcw生物科技公司 单链嵌合多肽和其用途
SG11202101779RA (en) 2018-08-30 2021-03-30 Hcw Biologics Inc Multi-chain chimeric polypeptides and uses thereof
EP3843756A2 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Methods of treating aging-related disorders
CA3116188A1 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
EP3897853A1 (en) 2018-12-20 2021-10-27 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
CA3119584A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
EP3898674A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN113490528A (zh) 2019-02-15 2021-10-08 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CN113329792B (zh) 2019-02-15 2024-06-28 诺华股份有限公司 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP3976182A4 (en) 2019-05-03 2023-01-18 Bioniz, LLC MODULATION OF THE EFFECTS OF GAMMA CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA-ASSOCIATED DISORDERS
KR20220012296A (ko) 2019-05-20 2022-02-03 싸이튠 파마 암 또는 감염성 질환 치료를 위한 IL-2/IL-15Rβγ 작용제 투여 요법
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
CA3143035A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
JP2022547154A (ja) 2019-09-10 2022-11-10 オブシディアン セラピューティクス， インコーポレイテッド 調節可能な制御のためのｃａ２－ｉｌ１５融合タンパク質
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
TW202128166A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 組合療法
EP4048285A1 (en) 2019-10-21 2022-08-31 Novartis AG Tim-3 inhibitors and uses thereof
CN115551594A (zh) * 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
CN111690068B (zh) * 2019-11-13 2022-04-19 中国科学技术大学 一种IL-15/SuIL-15Rα-dFc-γ4复合体蛋白及其构造方法、应用
US20230034677A1 (en) * 2019-11-21 2023-02-02 INSERM (Institut National de la Santé et la Recherche (Médicale) Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
BR112022012310A2 (pt) 2020-01-17 2022-09-06 Novartis Ag Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
EP3889183A1 (en) * 2020-04-01 2021-10-06 Pierre Fabre Medicament A protein complex comprising an immunocytokine
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
JP2023550880A (ja) 2020-10-26 2023-12-06 サイチューン ファーマ 非黒色腫皮膚癌を治療するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト
IL302321A (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15RBY agonist for the treatment of squamous cell carcinoma
MX2023005353A (es) 2020-11-06 2023-05-22 Novartis Ag Moleculas de union a cd19 y usos de las mismas.
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
IL307899A (en) * 2021-04-22 2023-12-01 Guangdong Fapon Biopharma Inc A bispecific multifunctional fusion polypeptide
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CA3220418A1 (en) 2021-06-23 2022-12-29 Guy Luc Michel De Martynoff Interleukin 15 variants
CA3225815A1 (en) 2021-08-13 2023-02-16 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
CN116023503B (zh) * 2021-10-25 2024-05-31 上海交通大学 一种融合蛋白及其制备方法和用途
WO2023083379A1 (zh) * 2021-11-15 2023-05-19 中国科学院生物物理研究所 一种以白介素15为活性成份的融合蛋白构建体及其应用
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN116854821A (zh) * 2022-08-15 2023-10-10 海徕科(北京)生物技术有限公司 IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576A (en) * 1838-01-20 Ftjbnace of stoves fob bubning anthracite
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0305967B1 (de) 1987-09-02 1993-05-05 Ciba-Geigy Ag Konjugate von Interferon alpha mit Immunglobulinen
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5108910A (en) 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU658396B2 (en) 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
PT772624E (pt) 1994-04-06 2001-03-30 Immunex Corp Interleucina-15
US6287865B1 (en) 1995-03-31 2001-09-11 Plant Bioscience Limited Cf-2 plant pathogen resistance genes
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR100704140B1 (ko) * 1999-02-12 2007-04-09 더 스크립스 리서치 인스티튜트 혈관형성 억제제 및 항-종양 면역요법제를 포함하는, 종양 및 전이를 치료하기 위한 약제학적 조성물 및 이를 포함하는 키트
US6319796B1 (en) 1999-08-18 2001-11-20 Vlsi Technology, Inc. Manufacture of an integrated circuit isolation structure
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
US6936704B1 (en) 1999-08-23 2005-08-30 Dana-Farber Cancer Institute, Inc. Nucleic acids encoding costimulatory molecule B7-4
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
JP4254051B2 (ja) 2000-11-15 2009-04-15 日本精工株式会社 トロイダル型無段変速機
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
US7186804B2 (en) 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
DE10212442A1 (de) 2002-03-20 2003-10-09 Michael Hesse Süßwasseraufbereitungsanlage und Verfahren zur Trinkwassergewinnung
US7906118B2 (en) 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
NZ581541A (en) 2002-10-17 2011-07-29 Genmab As Human monoclonal antibodies against CD20
US7858081B2 (en) 2004-02-27 2010-12-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) IL-15 mutants having agonists/antagonists activity
US20060025885A1 (en) 2004-08-02 2006-02-02 The Form House, Inc. Apparatus and method for loading data storage devices into carriers
PT1899364T (pt) 2005-05-17 2020-05-20 Univ Connecticut Composições e métodos para imunomodulação num organismo
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US9303080B2 (en) 2006-01-13 2016-04-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
JP2009536170A (ja) 2006-05-08 2009-10-08 フィロジェン・エッセペア 治療用の抗体標的指向サイトカイン
FR2906808B1 (fr) 2006-10-10 2012-10-05 Univ Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
ES2642008T3 (es) 2007-05-11 2017-11-14 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
ES2466916T3 (es) * 2007-06-27 2014-06-11 Admune Therapeutics Llc Complejos de IL-15 e IL-15R alfa y usos de los mismos
BRPI0814465B1 (pt) 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
PL2274008T3 (pl) 2008-03-27 2014-07-31 Zymogenetics Inc Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A
WO2009135031A1 (en) 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
EP2511294B1 (en) 2009-12-11 2014-02-26 Proyecto de Biomedicina Cima, S.L. Conjugates and compositions for immunotherapy and anti-tumoral treatment
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
CA2856895C (en) 2011-11-28 2021-10-26 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
ES2747997T3 (es) 2012-10-24 2020-03-12 Novartis Ag Formas de IL-15R alfa, células que expresan formas de IL-15R alfa, y usos terapéuticos de IL-15R alfa y complejos IL-15/IL-15R alfa

Also Published As

Publication number Publication date
JP2014524737A (ja) 2014-09-25
TR201907397T4 (tr) 2019-06-21
KR20220150407A (ko) 2022-11-10
DK2723869T3 (da) 2019-05-20
JP6452175B2 (ja) 2019-01-16
ES2727806T3 (es) 2019-10-18
BR112013033350B1 (pt) 2023-10-31
CN104093841A (zh) 2014-10-08
MX354923B (es) 2018-03-26
WO2012175222A8 (en) 2018-08-23
US20160318986A1 (en) 2016-11-03
RU2644671C2 (ru) 2018-02-13
KR101977312B1 (ko) 2019-05-13
JP2017184750A (ja) 2017-10-12
SI2723869T1 (sl) 2019-08-30
CN108341884A (zh) 2018-07-31
US10899816B2 (en) 2021-01-26
RU2017144606A (ru) 2019-03-04
US20240083963A1 (en) 2024-03-14
RU2014100350A (ru) 2015-07-27
PL2723869T3 (pl) 2019-09-30
AU2019240556A1 (en) 2019-10-17
EP2537933A1 (en) 2012-12-26
RU2017144606A3 (pt) 2021-02-10
US11753454B2 (en) 2023-09-12
AU2019240556B2 (en) 2022-01-13
JP2021098698A (ja) 2021-07-01
JP6151687B2 (ja) 2017-06-21
CN114805606A (zh) 2022-07-29
EP3406723A1 (en) 2018-11-28
AU2012272138A1 (en) 2014-01-16
KR102658284B1 (ko) 2024-04-18
US20180312560A1 (en) 2018-11-01
KR20140062030A (ko) 2014-05-22
KR20210016072A (ko) 2021-02-10
HRP20190799T1 (hr) 2019-08-23
KR20190051080A (ko) 2019-05-14
EP2723869B1 (en) 2019-02-27
WO2012175222A1 (en) 2012-12-27
US10626155B2 (en) 2020-04-21
AU2012272138B2 (en) 2017-07-20
AU2017245360B2 (en) 2019-07-18
JP2019054816A (ja) 2019-04-11
JP6913073B2 (ja) 2021-08-04
HUE043442T2 (hu) 2019-08-28
RU2763298C2 (ru) 2021-12-28
AU2017245360A1 (en) 2017-11-02
MX2013015393A (es) 2015-04-08
US20150152188A1 (en) 2015-06-04
CA2840113A1 (en) 2012-12-27
CA2840113C (en) 2024-02-27
US20210147503A1 (en) 2021-05-20
EP2723869A1 (en) 2014-04-30
JP7296999B2 (ja) 2023-06-23
BR112013033350A2 (pt) 2017-01-31

Similar Documents

Publication Publication Date Title
SI2723869T1 (sl) Imunocitokini na osnovi IL-15 in IL-15R alfa sushi domene
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
HRP20181472T1 (hr) Il-15 i il-15r-alpha "sushi domain" modulokini
IL221511A (en) Arilatriazolones associated with bis aryl and their use
EP2565263A4 (en) CULTURE MEDIA ADDITIVE AND USES THEREOF
PL2935475T3 (pl) Kompozycja tworząca warstwę izolacyjną i jej zastosowanie
IL222316A0 (en) Edible composition and uses thereof
ZA201208173B (en) Peptices and their use
EP2701730A4 (en) MFG-E8 AND USES THEREOF
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
HRP20182083T1 (hr) Nova kombinacija i uporaba
ZA201303656B (en) Cysteine and food intake
EP2697386A4 (en) DESIGN AND USE OF PEPDUCINE
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
EP2686335A4 (en) DECORINAL COMPOSITIONS AND THEIR USE
HK1198587A1 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2-
HK1154746A2 (en) Combination of pen and chopstick
AU333709S (en) Table and/or chair
TWM389472U (en) Combination of table and chairs
SG10201506940UA (en) Thioesterases and their use